Acelyrin

Biotech · Acquired

Izokibep, a monoclonal antibody IL-17A inhibitor therapeutic

acelyrin.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
21
0 granted · 21 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2240Monocacy Therapeutics Inc.—$389K
2241POWERHOUSE PROTEOMIC SYSTEMS, LLC——
2242TENSIVE CONTROLS, INC.——
2243Acelyrin——
2244Cour Pharmaceutical——
2245AVEXEGEN THERAPEUTICS INC.——
2246CELLF-BIO LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 21
  • Methods Of Treating Of Hidradenitis Suppurativaapplication
  • Methods Of Treating Ankylosing Spondylitisapplication
  • Methods Of Treating Hidradenitis Suppurativaapplication
  • Methods And Compositions Comprising Lonigutamab For Treating Tedapplication
  • Methods And Compositions Comprising Lonigutamab For Treating Tedapplication
  • Methods Of Treatment Of Psoriatic Arthritisapplication
  • Methods Of Treating Hidradenitis Suppurativaapplication
  • Methods For Use Of Izokibep To Treat Psaapplication
  • Methods Of Treating Hidradenitis Suppurativaapplication
  • Methods Of Treatment Of Uveitisapplication
  • Methods Of Treatment Of Psoriatic Arthritisapplication
  • Methods Of Treating Hidradenitis Suppurativaapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.